Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer’s Dacomitinib And More Biosimilar Hopefuls Among New EMA Filings

Executive Summary

There are eight new entries to the list of marketing applications filed with the European Medicines Agency, including submissions for more versions of Amgen’s Neulasta (pegfilgrastim), and a second biosimilar of Roche’s Avastin (bevacizumab).


Related Content

EU Safety Updates For Lenalidomide, Pegfilgrastim & Pembrolizumab
ATMP For Metastatic Cervical Cancer Among Nine New Products Under EMA Review
Two Hopefuls And A ‘No’: EMA Decisions On Accelerated Access
New EU Submissions For Pfizer’s Lorlatinib, Teva’s Fremanezumab - And A CV Filing For Canakinumab
Amgen Wins First EU Avastin Biosimilar Approval, But When Will It Launch?
First Biosimilar MabThera One Step Away from EU Approval; Pegfilgrastim Filings Withdrawn


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts